Artificial tears, other eye products recalled; consumers urged to discontinue use
Over-the-counter ophthalmic products were voluntarily recalled due to a manufacturing deviation discovered during a U.S. Food and Drug Administration audit, a notice says.
Pharmaceutical distributor AvKARE was notified of the consumer level drug recall by the recalling firm, BRS Analytical Services LLC. The recall was issued for several products as a result of manufacturing deviations that "may lead to products of unacceptable quality, and it is not possible to rule out patient risks resulting from use of these products."
The notice warns consumers to stop using the affected products immediately. AvKARE said the FDA is aware of the recall, and the health hazard linked to the items is unknown.
USA TODAY reached out to AvKARE for more information.
Car recalls: Volvo, Volkswagen, Polestar among over 500,000 vehicles recalled
When were the items distributed?
The recalled products were shipped from May 26, 2023, to April 21, 2025, AvKARE said.
Which products were voluntarily recalled?
AvKARE's press release includes a detailed chart with the lot numbers and expiration dates of the recalled products below. A recall notice posted on the FDA's website identified the amount of cases involved in the recall.
13,104 cases of Lubricant Eye Drops Solution; national drug code (NDC): 50268-126-15
32,876 cases of Carboxymethylcellulose Sodium Ophthalmic Solution; national drug code (NDC): 50268-068-15
14,333 cases of Polyvinyl Alcohol Ophthalmic Solution; national drug code (NDC): 50268-678-15
1,610 cases of Carboxymethylcellulose Sodium Ophthalmic Gel 1%; national drug code (NDC): 50268-066-15
13,872 cases of Artificial Tears Ophthalmic Solution; national drug code (NDC): 50268-043-15
What should consumers do?
Buyers who may have these recalled products in their inventory are urged to complete a downloadable PDF "Quality to Return" form attached to the recall notice and fax it to 931-292-6229 or email it to customerservice@avkare.com.
Then, the company will send the customer a "Return to Authorization Form" to ship the recalled product back to the listed address to get a full credit, including shipping costs.
Taylor Ardrey is a news reporter for USA TODAY. You can reach her at tardrey@gannett.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
FDA recalls more than 64,000 pounds of butter over undeclared milk
More than 64,000 pounds of butter have been recalled due to potential undeclared milk allergens, according to the U.S. Food and Drug Administration. Food ingredient company Bunge North America recalled 1,800 cases of its NH European Style Butter Blend that were distributed at 12 centers located across the United States and one in Dominican Republic, a July 14 FDA alert reported. The FDA classified the recall under its second-highest risk warning on July 31 warning that consumption could pose temporary or medically reversible adverse health consequences. USA TODAY has reached out to Bunge North America for comment. Based in Chesterfield, Missouri, Bunge North America is an agribusiness that produces and markets multiple food ingredients including corn, wheat, rice, soybeans and feed peas. Which butter products are recalled? The FDA has issued a recall for 64,800 pounds of Bunge North America's NH European Style Butter Blend with: UPC code: 1 00 78684 73961 2 Lot code: 5064036503 The product was packaged in white paperboard cases each containing 36 blocks. This article originally appeared on USA TODAY: FDA recalls more than 64,000 pounds of butter over undeclared milk
Yahoo
7 hours ago
- Yahoo
Boston Scientific Stock Outlook: Is Wall Street Bullish or Bearish?
Boston Scientific Corporation (BSX), headquartered in Marlborough, Massachusetts, develops, manufactures, and markets medical devices for use in various interventional medical specialties globally. With a market cap of $157.9 billion, the company's products are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, and more. Shares of this medTech giant have outperformed the broader market over the past year. BSX has gained 41.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 16.6%. In 2025, BSX stock is up 17.5%, surpassing the SPX's 7.8% rise on a YTD basis. More News from Barchart With UnitedHealth Under DOJ Investigation, Should You Buy, Sell, or Hold UNH Stock Now? Trump Won't Take Away Tesla's Subsidies. Does That Make TSLA Stock a Safe Buy Here? Can AMD Stock Hit $210 in 2025? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Zooming in further, BSX's outperformance is also apparent compared to the iShares U.S. Medical Devices ETF (IHI). The exchange-traded fund has gained about 9% over the past year. Moreover, BSX's double-digit gains on a YTD basis outshine the ETF's 2.3% gains over the same time frame. BSX's strong performance can be credited to its robust product portfolio and dedicated global team. Key achievements in the second quarter include FDA approval for expanding the FARAPULSE PFA System, initiation of the ReMATCH IDE trial, and securing CE Mark for the WATCHMAN FLX Pro device in Europe. The company also finalized the acquisitions of Intera Oncology and SoniVie, enhancing its offerings in liver cancer and hypertension treatment technologies. On Jul. 23, BSX shares closed up more than 4% after reporting its Q2 results. Its adjusted EPS of $0.75 beat Wall Street's expectations of $0.72. The company's revenue was $5.1 billion, exceeding Wall Street forecasts of $4.9 billion. The company expects full-year adjusted EPS in the range of $2.95 to $2.99. For the current fiscal year, ending in December, analysts expect BSX's EPS to grow 18.7% to $2.98 on a diluted basis. The company's earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters. Among the 30 analysts covering BSX stock, the consensus is a 'Strong Buy.' That's based on 27 'Strong Buy' ratings, two 'Moderate Buys,' and one 'Hold.' This configuration is more bullish than two months ago, with 26 analysts suggesting a 'Strong Buy.' On Jul. 24, Raymond James Financial, Inc. (RJF) analyst Jayson Bedford maintained a 'Buy' rating on BSX with a price target of $124, implying a potential upside of 18.2% from current levels. The mean price target of $124.53 represents an 18.7% premium to BSX's current price levels. The Street-high price target of $140 suggests an ambitious upside potential of 33.4%. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
9 hours ago
- Yahoo
DOJ reaches $9.8 million settlement with Illumina over cyber whistleblower claims
This story was originally published on Cybersecurity Dive. To receive daily news and insights, subscribe to our free daily Cybersecurity Dive newsletter. The Department of Justice on Thursday announced a $9.8 million settlement with Illumina over allegations that the company sold genomic-sequencing systems with software vulnerabilities to federal agencies for multiple years. Between 2016 and 2023, the government said, the company sold the systems without having an adequate security program and knowingly failed to incorporate cybersecurity into its product design process. According to prosecutors' complaint, Illumina is the dominant company in the global market, with a share of roughly 80%. 'Companies that sell products to the federal government will be held accountable for failing to adhere to cybersecurity standards and protecting against cybersecurity risks,' Assistant Attorney General Brett Shumate of the DOJ's Civil Division said in a statement. 'This settlement underscores the importance of cybersecurity in handling genetic information and the department's commitment to ensuring that federal contractors adhere to requirements to protect sensitive information from cyber threats,' he added. Illumina denied the allegations that it knowingly sold defective products, and the agreement states that the company is not making any admissions related to those claims. The Food and Drug Administration in 2023 issued a warning about a vulnerability in Illumina software that could allow an attacker to change settings on the device or even take it over remotely. In 2022, the Cybersecurity and Infrastructure Security Agency warned about a flaw in Illumina's Local Run Manager software that could allow an attacker to remotely alter test results. The company later patched the flaw. The case involved a whistleblower — Erica Lenore, a former director of platform management at Illumina — who provided the government with details about the company's alleged noncompliance. Lenore will receive $1.9 million from the settlement. Illumina said while it disagrees with the allegations from the government, it decided to settle the matter due to the 'uncertainty, expense and distraction' of litigating the case. The company noted the claims related to software issues, which Illumina says it successfully remediated from 2022 to 2024. 'Government agencies, including the U.S. Food and Drug Administration (FDA), are important customers and Illumina values these relationships,' the company said in a statement. 'Illumina takes data security seriously and has invested significantly in its programs to align with cybersecurity best practices for the development and deployment of our products. DOJ also reached a $1.75 million settlement with defense contractor Aero Turbine Inc. and private equity firm Galant Capital Partners, over claims they failed to meet cybersecurity standards related to an Air Force contract. The DOJ did credit them for voluntarily coming forward to cooperate in the case. (Updates with comments from company) Recommended Reading US government plays catchup on phishing-resistant MFA Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
